Essentials · Evidence reviewed
Can you stay on a lower dose of Wegovy or Zepbound?
Do you really need to keep increasing your weight-loss medication dose? Researchers have tested different doses, while FDA prescribing instructions explain which doses are considered maintenance treatment. The answer is more nuanced than simply 'higher is better'.
What did researchers test?
In Novo Nordisk-funded STEP 2, adults with excess weight and type 2 diabetes were randomly assigned to semaglutide 2.4 mg, semaglutide 1.0 mg or placebo. At 68 weeks, average weight changes were about −9.6%, −7.0% and −3.4%, respectively. Those are group averages in adults with diabetes, not a dose-by-dose prediction for every Wegovy patient.
What about Zepbound?
Eli Lilly-supported SURMOUNT-1 studied tirzepatide at maintenance doses of 5 mg, 10 mg and 15 mg in adults without diabetes. Average weight reductions at 72 weeks were about 15.0%, 19.5% and 20.9%, respectively. That shows meaningful average weight loss was possible at 5 mg, though higher study doses generally produced greater average reductions.
What does 'maintenance dose' mean?
A starting dose is often used to help the body adjust. A maintenance dose is the ongoing regimen supported by the particular product's label. Zepbound's dosing instructions and Wegovy's formulations have their own schedules and options. Staying at a particular dose depends on tolerability, medical response, indication and your clinician's assessment—not on a website chart.
What should you ask your prescriber?
Ask whether your current dose is an approved maintenance option, whether your progress and side effects support remaining there, and what might change if the dose is increased. Insurance coverage and cost may also vary by strength and formulation. Never alter a prescription based only on trial averages.
The bottom line
Yes, lower maintenance doses can be appropriate for some people, but starter doses and approved maintenance doses are not interchangeable. The dose decision is individual.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2021-03-13. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceAdditional evidenceThis guide explains published evidence; source dates may be older than the review date. Our interpretation is educational and does not replace medical or insurance advice.